Ping Yuan

Ping Yuan

Auto-generated profile, based on publicly available information

Ping Yuan

Department of Thoracic Surgery The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan China

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2006 in Cancer
Verified
Journal Article
Open access
PDF file
PYPing Yuan
Ping Yuan
STStephane Temam
Stephane Temam
AEAdel K. El-Naggar
Adel K. El-Naggar
XZXian Zhou
Xian Zhou
DLDiane D. Liu
Diane D. Liu
LMLi Mao
Li Mao
BACKGROUND.: Podoplanin is a mucin‐like glycoprotein that is important in lymphangiogenesis but not blood vessel formation. Recent studies suggested a potential role of podoplanin in certain tumor cells. The purpose of the current study was to determine the role of podoplanin in head and neck squamous cell carcinoma (HNSCC).METHODS.: Podoplanin expression was analyzed in 35 patients with HNSCC including 16 oral tumors and 19 hypopharyngeal tumors by immunohistochemical analysis and the association between the podoplanin expression status and patients' clinical and pathologic characteristics was evaluated. An independent set of 60 patients with oral tongue cancer was then analyzed for associations between the podoplanin expression status and patients' clinical and pathologic characteristics, including survivals.RESULTS.: Podoplanin was not expressed in normal oral epithelial cells but was detected in some hyperplastic and dysplastic lesions. High podoplanin expression was found in 20 (57%) of the 35 tumors and was more frequent in tumors with lymph node metastasis, particularly for tumors in the oral cavity. In the second set of 60 oral tongue cancers, 36 (60%) expressed high levels of podoplanin. Patients whose tumors expressed high levels of podoplanin had a statistically significantly higher rate of lymph node metastasis (P < .0001). Patients with lymph node metastasis and high‐level podoplanin showed the shortest disease‐specific survival (P = .0004) than other patients.CONCLUSIONS.: Podoplanin is involved in oral tumorigenesis and may serve as a predictor for lymph node metastasis and poor clinical outcome. Cancer 2006. © 2006 American Cancer Society.

12 November 2024 in Cancer Imaging
Verified
Journal Article
Open access
PDF file
PYPing Yuan
Ping Yuan
ZHZhen-Hao Huang
Zhen-Hao Huang
YYYun-Hai Yang
Yun-Hai Yang
FBFei-Chao Bao
Fei-Chao Bao
KSKe Sun
Ke Sun
Yu QiYu Qi
Yu Qi
Background: To develop an artificial intelligence (AI)-based model using Radiomics, deep learning (DL) features extracted from 18F-fluorodeoxyglucose (18F-FDG) Positron emission tomography/Computed Tomography (PET/CT) images of tumor and cervical lymph node with clinical feature for predicting cervical lymph node metastasis (CLNM) in patients with esophageal squamous cell carcinoma (ESCC). Methods: The study included 300 ESCC patients from the First Affiliated Hospital of Zhengzhou University who were divided into a training cohort and an internal testing cohort with an 8:2 ratio. Another 111 patients from Shanghai Chest Hospital were included as the external cohort. For each sample, we extracted 428 PET/CT-based Radiomics features from the gross tumor volume (GTV) and cervical lymph node (CLN) delineated layer by layer and 256 PET/CT-based DL features from the maximum cross-section of GTV and CLN images We input these features into seven different machine learning algorithms and ultimately selected logistic regression (LR) as the model classifier. Subsequently, we evaluated seven models (Clinical, Radiomics, Radiomics-Clinical, DL-Clinical, DL-Radiomics, DL-Radiomics-Clinical) using Radiomics features, DL features and clinical feature. Results: The DL-Radiomics-Clinical (DRC) model demonstrated higher AUC of 0.955 and 0.916 compared to the other six models in both internal and external testing cohorts respectively. The DRC model achieved the highest accuracy among the seven models in both the internal and external test sets, with scores of 0.951 and 0.892, respectively. Conclusions: Through the combination of Radiomics features and DL features from PET/CT imaging and clinical feature, we developed a predictive model exhibiting exceptional classification capabilities. This model can be considered as a non-invasive method for predication of CLNM in patients with ESCC. It might facilitate decision-making regarding to the extend of lymph node dissection, and to select candidates for postoperative adjuvant therapy.

2 March 2024 in Vaccine
Verified
Journal Article
Closed access
XDXiaoxia Duan
Xiaoxia Duan
LZLiangzhi Zhang
Liangzhi Zhang
LDLing Ding
Ling Ding
CZChaoyong Zhang
Chaoyong Zhang
ZCZhenhua Chen
Zhenhua Chen
LLLu Long
Lu Long

5 May 2025 in Thoracic Cancer
Verified
Journal Article
Open access
PYPing Yuan
Ping Yuan
ZHZhenhao Huang
Zhenhao Huang
FBFeichao Bao
Feichao Bao
JLJiajing Li
Jiajing Li
LCLidong Chen
Lidong Chen
XLXiangnan Li
Xiangnan Li
Objective: To evaluate thoraco‐laparoscopic McKeown esophagectomy (TLME) versus endoscopic submucosal dissection (ESD) for clinical‐T1N0 esophageal squamous cell carcinoma (ESCC) depending on invasion depth.Background: Early‐stage ESCC has been widely treated by endoscopic resection. While ESD is safer than esophagectomy perioperatively, its survival benefits for clinical‐T1N0M0 ESCC, especially high‐risk T1b tumors, are unclear.Methods: A retrospective study was conducted on clinical‐T1N0 ESCC patients at the First Affiliated Hospital of Zhengzhou University comparing TLME (cT1a, n = 352; cT1b, n = 205) with ESD (cT1a, n = 499; cT1b, n = 62). Overall survival (OS), disease‐specific survival (DSS), relapse‐free survival (RFS), and metastasis‐free survival (MFS) were analyzed depending on invasion depth after propensity score matching to account for selection bias.Results: ESD group had better OS (hazard ratio: 0.54, p = 0.029) but worse RFS (hazard ratio: 6.83, p < 0.001) than TLME group in general terms. T1a cancers showed no difference in DSS and MFS between groups. T1b subgroup with ESD had lower DSS (hazard ratio: 5.65, p = 0.036) and MFS (hazard ratio: 3.54, p = 0.069). R1‐resection in ESD group linked to poorer OS (hazard ratio: 5.89, p = 0.006) and DSS (hazard ratio: 3.67, p = 0.006).Conclusion: ESD can be safe in the treatment of clinical‐T1aN0 ESCC. However, concerning oncologic curability, TLME should be recommended for patients with clinical‐T1bN0 ESCC in terms of favorable DSS, RFS, and MFS.

23 February 2017
Verified
Journal Article
Closed access
Ting FengTing Feng
Ting Feng
HLH M Li
H M Li
PYP Yuan
P Yuan
DYD K Yu
D K Yu
FMF Ma
F Ma
WTW Tan
W Tan
Objective: To explore the associations between genetic variations of glutathione synthetase gene (GSS) and response to platinum-based chemotherapy of small cell lung cancer(SCLC), and to analyze the influencing factors on survival. Methods: Four haplotype-tagging single nucleotide polymorphisms (htSNPs) of GSS were genotyped by Sequenom MassARRAY methods in 903 SCLC patients who received platinum-based chemotherapy, and had different response and survival time. The associations between genotypes and platinum-based chemotherapy response were measured by odds ratios (OR) and 95% confidence intervals (CI), adjusted for sex, age, smoking, KPS, staging and chemotherapy regiments, by unconditional logistic regression model. The hazard ratios (HR) were estimated by Cox proportional hazards regression model. Results: Among the 903 patients, 462(51.2%) cases received cis-platinum and etoposide treatment while others were treated with carboplatin and etoposide. 656 patients were chemotherapy responders in the study with a response rate of 72.6%. Patients were followed up to get their survival information. The median survival time (MST) of these patients was 25.0 months.We found that rs725521 located in the 3' near gene region of GSS was significantly associated with chemotherapy response. Compared with the T allele, patients with C allele had a worse chemotherapy response and an increased risk of no-responders (P=0.027). Rs7265992 and rs725521 of GSS were associated with the overall survival (OS) of SCLC patients who received platinum-based chemotherapy (HR=1.16, 95% CI=1.02-1.33, P=0.027; HR=1.17, 95% CI=1.05-1.31, P=0.006, respectively). The patients carrying 1 or 2 risk alleles and the patients carrying 3 or 4 risk alleles had worse MST than the patients without the rs7265992A and rs725521C risk alleles (24.0 and 22.0 versus 30.0 months), with the HR for death being 1.26 (95% CI=1.04-1.54) and with the HR of 1.52 (95%CI=1.18-1.97, P=0.001). Rs2025096 and rs2273684 were not associated with the OS of SCLC patients who received platinum-based chemotherapy. Age ≤ 56, KPS> 80, limited-stage, chemotherapy response and radiation therapy had a remarkably prolonged OS (all P<0.05). Conclusions: These results suggest that GSS genetic polymorphism rs725521 plays an important role in the response to platinum-based chemotherapy, while rs7265992 and rs725521 have important effect on the prognosis of SCLC patients, which may be potential genetic biomarkers for personalized treatment of SCLC.

15 February 2016 in Cancer Research
Verified
Journal Article
Closed access
YHYuguang Huang
Yuguang Huang
PYP Yuan
P Yuan
FDF Du
F Du
XDX Ding
X Ding
BXB Xu
B Xu
Background: SPARC (secreted protein acidic and rich in cystein) is a secreted glycoprotein that interacts with extracellular matrix protein and acts as a regulator of critical cellular functions such as proliferation and cell migration. An increasing number of studies have shown altered expression of SPARC in several malignancies. However, the role of this potential biomarker in breast cancer development and progression is controversial. Triple-negative breast cancer (TNBC) is known for its poor prognosis and high recurrence probability. There is a need for prognostic biomarkers to guide treatment decisions for this subtype.